Ianevski A - Search Results

1

The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL.

Otte M, Stachelscheid J, Glaß M, Wahnschaffe L, Jiang Q, Lone W, Ianevski A, Aittokallio T, Iqbal J, Hallek M, Hüttelmaier S, Schrader A, Braun T, Herling M. Otte M, et al. Among authors: ianevski a. Cancers (Basel). 2023 Apr 28;15(9):2527. doi: 10.3390/cancers15092527. Cancers (Basel). 2023. PMID: 37173993 Free PMC article.

2

[No title available]

[No authors listed] [No authors listed] PMID: 32959065

3

SynergyFinder 2.0: visual analytics of multi-drug combination synergies.

Ianevski A, Giri AK, Aittokallio T. Ianevski A, et al. Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493. doi: 10.1093/nar/gkaa216. Nucleic Acids Res. 2020. PMID: 32246720 Free PMC article.

4

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.

Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M, Gunning PT. Toutah K, et al. Among authors: ianevski a. J Med Chem. 2021 Jun 24;64(12):8486-8509. doi: 10.1021/acs.jmedchem.1c00420. Epub 2021 Jun 8. J Med Chem. 2021. PMID: 34101461 Free PMC article.

5

Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data.

Ianevski A, Giri AK, Aittokallio T. Ianevski A, et al. Nat Commun. 2022 Mar 10;13(1):1246. doi: 10.1038/s41467-022-28803-w. Nat Commun. 2022. PMID: 35273156 Free PMC article.

6

SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.

Ianevski A, Giri AK, Aittokallio T. Ianevski A, et al. Nucleic Acids Res. 2022 Jul 5;50(W1):W739-W743. doi: 10.1093/nar/gkac382. Nucleic Acids Res. 2022. PMID: 35580060 Free PMC article.

7

Genome-wide off-targets of drugs: risks and opportunities.

Giri AK, Ianevski A, Aittokallio T. Giri AK, et al. Among authors: ianevski a. Cell Biol Toxicol. 2019 Dec;35(6):485-487. doi: 10.1007/s10565-019-09491-7. Epub 2019 Aug 20. Cell Biol Toxicol. 2019. PMID: 31432301 No abstract available.

8

Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells.

Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T. Athanasiadis P, et al. Among authors: ianevski a. Methods Mol Biol. 2022;2449:327-348. doi: 10.1007/978-1-0716-2095-3_14. Methods Mol Biol. 2022. PMID: 35507270

9

SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Ianevski A, He L, Aittokallio T, Tang J. Ianevski A, et al. Bioinformatics. 2017 Aug 1;33(15):2413-2415. doi: 10.1093/bioinformatics/btx162. Bioinformatics. 2017. PMID: 28379339 Free PMC article.

10

SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.

Ianevski A, Timonen S, Kononov A, Aittokallio T, Giri AK. Ianevski A, et al. PLoS Comput Biol. 2020 Feb 3;16(2):e1007604. doi: 10.1371/journal.pcbi.1007604. eCollection 2020 Feb. PLoS Comput Biol. 2020. PMID: 32012154 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page